Resmed INC Form 4 insider transactions

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at a price of $233.47 on October 8, 2024, according to a Form 4 filing with the SEC.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock on October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock on October 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Kaushik Ghoshal, Chief Commercial Officer, SaaS at ResMed, exercised stock options and sold shares on September 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, executed a sale of 1,000 shares of ResMed common stock at a price of $246.42 per share on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of the company's common stock on September 4, 2024, at a price of $239.9 per share.

Director Christopher DelOrefice reported the acquisition of 267 restricted stock units (RSUs) in ResMed Inc.

Global General Counsel Michael J. Rider sold 882 shares of ResMed Inc. stock on August 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Financial Officer of ResMed, Brett Sandercock, reports the acquisition of ResMed common stock following the vesting of performance-based restricted stock units.

Global General Counsel Michael J. Rider reports acquiring shares of ResMed Inc. through the vesting of performance-based restricted stock units.

Chief Product Officer of ResMed Inc., Justin Leong, reports the acquisition of shares related to performance-based restricted stock units.

Kaushik Ghoshal, President of SaaS Business at ResMed, acquired shares of ResMed common stock on August 15, 2024, following the vesting of performance-based restricted stock units.

ResMed's CEO, Michael J. Farrell, reports the acquisition of shares due to the vesting of performance-based restricted stock units.

Kaushik Ghoshal, President of SaaS Business at ResMed, exercised stock options and sold 10,000 shares of ResMed common stock on August 12, 2024, according to a Form 4 filing with the SEC.

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of common stock at a price of $212.16 per share on August 8, 2024, under a pre-arranged 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock on August 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Justin Leong, President of Asia and Latin America at ResMed Inc., sold 48,000 shares of ReMed Common Stock on August 5, 2024.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock on July 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, executed a sale of 1,000 shares of ResMed Common Stock at a price of $194.35 per share on July 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at a price of $209.81 per share on June 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed common stock under a pre-arranged Rule 10b5-1 trading plan.

Michael J. Rider, Global General Counsel of ResMed Inc., reports a disposition of shares for tax withholding and stock purchase plan activity.

Director Carol Burt reported a gift of ResMed shares to The Nature Conservancy on May 24, 2024.

ResMed director Jan De Witte amended a previous SEC filing to indicate a stock sale was executed under a pre-arranged Rule 10b5-1 trading plan.

Director Peter C. Farrell gifted 68,200 shares of ResMed common stock to a charitable remainder trust, resulting in a decrease in his directly held shares.

Director Jan De Witte sold 360 shares of ResMed Inc. on May 15, 2024, at a price of $218.29 per share.

ResMed's Chief Financial Officer, Brett Sandercock, exercised stock options and sold shares of ResMed common stock on May 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Director Carol Burt reported a gift of ResMed shares to a charitable organization on April 29, 2024.